CVRx Reports Q4 & FY25 Results, Initiates Landmark BENEFIT-HF Trial, and Secures Liquidity
CVRX sits 32% above its 52-week low of $4.299.
Summary
CVRx reported Q4 and full-year 2025 financial results, highlighting revenue growth and improved gross margins, alongside the initiation of a pivotal clinical trial and favorable reimbursement changes, while also confirming recent debt facility expansion for liquidity.
Key Events · Earnings and Guidance · CVRX
-
Reports Q4 and Full Year 2025 Financial Results
Q4 2025 revenue increased 4% to $16.0 million, with a net loss of $11.9 million. Full-year 2025 revenue grew 10% to $56.7 million, and net loss improved to $53.3 million. Gross margin for the full year reached 85%.
-
Initiates Landmark BENEFIT-HF Clinical Trial
The company announced the initiation of the BENEFIT-HF trial, a randomized controlled trial designed to evaluate Barostim's impact on an expanded heart failure patient population, potentially tripling the addressable market. Enrollment is expected to begin in Q2 2026.
-
Favorable Reimbursement Changes Effective
New Category I CPT codes and favorable physician fee payment levels took effect on January 1, 2026, which are expected to remove automatic prior authorization denials and support increased adoption of Barostim therapy.
-
Provides 2026 Financial Outlook
For the full year 2026, CVRx expects total revenue between $63.0 million and $67.0 million, with gross margin between 84% and 86%. Q1 2026 revenue is projected between $13.7 million and $14.7 million.
Analysis · CVRX · Industrial Applications And Services
CVRx, Inc. reported mixed financial results for Q4 2025, with revenue increasing 4% year-over-year to $16.0 million, but net loss widening to $11.9 million. However, full-year 2025 results showed stronger growth, with revenue up 10% to $56.7 million and a reduced net loss of $53.3 million compared to the prior year. The company's gross margin improved to 86% in Q4 and 85% for the full year, indicating increased manufacturing efficiencies. Strategically, the initiation of the BENEFIT-HF trial is a significant long-term catalyst, potentially tripling the addressable market for its Barostim therapy. The implementation of new Category I CPT codes is also expected to streamline reimbursement and reduce prior authorization denials, which should support sales growth. While Q1 2026 revenue guidance of $13.7 million to $14.7 million suggests a sequential slowdown, the full-year 2026 revenue guidance of $63.0 million to $67.0 million implies continued double-digit growth. The previously announced amendment to its debt facility, increasing it to $100 million and drawing an additional $10 million, provides crucial liquidity to fund operations and the BENEFIT-HF trial, addressing the company's cash burn of $40.8 million in 2025.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 29% of the 1653 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVRX was trading at $5.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $149.1M. The 52-week trading range was $4.30 to $15.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.